AU2022236485A1 - Long acting injectable formulation comprising risperidone and biodegradable polymers - Google Patents

Long acting injectable formulation comprising risperidone and biodegradable polymers Download PDF

Info

Publication number
AU2022236485A1
AU2022236485A1 AU2022236485A AU2022236485A AU2022236485A1 AU 2022236485 A1 AU2022236485 A1 AU 2022236485A1 AU 2022236485 A AU2022236485 A AU 2022236485A AU 2022236485 A AU2022236485 A AU 2022236485A AU 2022236485 A1 AU2022236485 A1 AU 2022236485A1
Authority
AU
Australia
Prior art keywords
risperidone
formulation
long acting
acting injectable
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022236485A
Other languages
English (en)
Inventor
Anna ELGART VALITSKY
Eran HARARY
Avia MERENLENDER WAGNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedinCell SA
Original Assignee
MedinCell SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedinCell SA filed Critical MedinCell SA
Publication of AU2022236485A1 publication Critical patent/AU2022236485A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022236485A 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers Pending AU2022236485A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163162272P 2021-03-17 2021-03-17
US63/162,272 2021-03-17
IB2021052248 2021-03-17
IBPCT/IB2021/052248 2021-03-17
US202163208860P 2021-06-09 2021-06-09
US63/208,860 2021-06-09
US202163270174P 2021-10-21 2021-10-21
US63/270,174 2021-10-21
PCT/EP2022/057009 WO2022195018A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Publications (1)

Publication Number Publication Date
AU2022236485A1 true AU2022236485A1 (en) 2023-08-24

Family

ID=81307068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022236485A Pending AU2022236485A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Country Status (10)

Country Link
US (2) US20240148641A1 (enExample)
EP (1) EP4308077A1 (enExample)
JP (1) JP2024511353A (enExample)
KR (1) KR20230158088A (enExample)
AU (1) AU2022236485A1 (enExample)
BR (1) BR112023018652A2 (enExample)
CA (1) CA3208006A1 (enExample)
IL (1) IL304980A (enExample)
MX (1) MX2023010925A (enExample)
WO (1) WO2022195018A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501805A (ja) * 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
US10463607B2 (en) * 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
KR101424163B1 (ko) * 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
US9023897B2 (en) * 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
EP2866837B1 (en) 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
CN107213136B (zh) * 2017-06-07 2021-06-01 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法
WO2020154315A1 (en) * 2019-01-22 2020-07-30 Indivior Uk Limited Methods for treating schizophrenia
MX2022003051A (es) * 2019-09-13 2022-06-14 Medincell S A Formulaciones para la administracion de farmacos.

Also Published As

Publication number Publication date
BR112023018652A2 (pt) 2023-10-03
MX2023010925A (es) 2023-09-27
US12329851B2 (en) 2025-06-17
EP4308077A1 (en) 2024-01-24
WO2022195018A1 (en) 2022-09-22
JP2024511353A (ja) 2024-03-13
US20240148641A1 (en) 2024-05-09
KR20230158088A (ko) 2023-11-17
US20240325293A1 (en) 2024-10-03
CA3208006A1 (en) 2022-09-22
IL304980A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
ES2868353T3 (es) Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
US12128132B2 (en) Drug delivery formulations
JP7030813B2 (ja) 前立腺癌の処置のためのシロリムスの腫瘍内投与
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
JP2023552329A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2023551009A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
US12472184B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
US12220418B2 (en) Olanzapine compositions and methods of use
JP2022088622A (ja) がん療法のためのメトロノミック経口ゲムシタビン
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
HK40120254B (en) Olanzapine compositions and methods of use
HK40120254A (en) Olanzapine compositions and methods of use
BR122025009310A2 (pt) Formulações de entrega de fármaco